Payment overview · 2025
General Payments
$560.13
25 reported records · 12 companies
Healthcare provider profile · identity verified
Amy Katherine Simpson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TYLER, TX · NPI 1346349289
Verified facts
What the public records show
CMS Open Payments records show Amy Katherine Simpson, M.D. received $560.13 in general payments during 2025 across 25 reported records.
Novartis Pharmaceuticals Corporation accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $97.50 | 17.4% | 6 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $93.28 | 16.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $80.76 | 14.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.99 | 11.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.97 | 10.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.03 | 9.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.32 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.66 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.56 | 3.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.98 | 3.0% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $16.61 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.47 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $560.13 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $97.50 | 6 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $93.28 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $80.76 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.99 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $53.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.07 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 108 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
165 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 860 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 738 | 190 |
| Losartan Potassium | Losartan Potassium | 578 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 470 | 130 |
| Gabapentin | Gabapentin | 460 | 114 |
| Estradiol | Estradiol | 356 | 100 |
| Omeprazole | Omeprazole | 337 | 99 |
| Alprazolam | Alprazolam | 318 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 91 |
| Simvastatin | Simvastatin | 285 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 253 | 72 |
| Trazodone Hcl | Trazodone Hcl | 252 | 51 |
| Alendronate Sodium | Alendronate Sodium | 242 | 65 |
| Tramadol Hcl | Tramadol Hcl | 241 | 64 |
| Fluoxetine Hcl | Fluoxetine Hcl | 238 | 58 |
| Ezetimibe | Ezetimibe | 233 | 59 |
| Lisinopril | Lisinopril | 229 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 226 | 55 |
| Ozempic | Semaglutide | 222 | 32 |
| Potassium Chloride | Potassium Chloride | 203 | 59 |
| Metformin Hcl | Metformin Hcl | 202 | 48 |
| Bupropion Xl | Bupropion Hcl | 199 | 48 |
| Metformin Hcl Er | Metformin Hcl | 191 | 59 |
| Celecoxib | Celecoxib | 189 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 54 |
| Irbesartan | Irbesartan | 185 | 41 |
| Meloxicam | Meloxicam | 180 | 47 |
| Montelukast Sodium | Montelukast Sodium | 177 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 34 |
| Carvedilol | Carvedilol | 167 | 45 |
| Synthroid | Levothyroxine Sodium | 165 | 39 |
| Temazepam | Temazepam | 165 | 27 |
| Furosemide | Furosemide | 161 | 45 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 159 | 37 |
| Donepezil Hcl | Donepezil Hcl | 157 | 45 |
| Spironolactone | Spironolactone | 156 | 41 |
| Sertraline Hcl | Sertraline Hcl | 155 | 40 |
| Azithromycin | Azithromycin | 154 | 133 |
| Glimepiride | Glimepiride | 147 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 120 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 28 |
| Clonazepam | Clonazepam | 113 | 17 |
| Valsartan | Valsartan | 112 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 33 |
| Eliquis | Apixaban | 108 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 104 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 26 |
| Memantine Hcl | Memantine Hcl | 102 | 24 |
| Valacyclovir | Valacyclovir Hcl | 102 | 46 |
| Famotidine | Famotidine | 95 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 37 |
| Allopurinol | Allopurinol | 93 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 29 |
| Methocarbamol | Methocarbamol | 87 | 31 |
| Prednisone | Prednisone | 85 | 49 |
| Lorazepam | Lorazepam | 82 | 18 |
| Buspirone Hcl | Buspirone Hcl | 80 | 23 |
| Premarin | Estrogens, Conjugated | 80 | 20 |
| Fenofibrate | Fenofibrate | 78 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 18 |
| Colestipol Hcl | Colestipol Hcl | 76 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 61 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 26 |
| Pregabalin | Pregabalin | 74 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 22 |
| Januvia | Sitagliptin Phosphate | 70 | 14 |
| Methylprednisolone | Methylprednisolone | 69 | 61 |
| Repatha Sureclick | Evolocumab | 68 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 14 |
| Mounjaro | Tirzepatide | 65 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 11 |
| Minoxidil | Minoxidil | 62 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 14 |
| Mirtazapine | Mirtazapine | 54 | 12 |
| Ramipril | Ramipril | 53 | 15 |
| Clonidine Hcl | Clonidine Hcl | 50 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 12 |
| Myrbetriq | Mirabegron | 49 | 11 |
| Topiramate | Topiramate | 49 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 11 |
| Verapamil Er | Verapamil Hcl | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 11 |
| Lidocaine | Lidocaine | 34 | suppressed |
| Metronidazole | Metronidazole | 33 | 15 |
| Telmisartan | Telmisartan | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 13 |
| Fluconazole | Fluconazole | 32 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | 11 |
| Ondansetron Odt | Ondansetron | 29 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 24 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Mirabegron Er | Mirabegron | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Gemtesa | Vibegron | 26 | 13 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Prempro | Estrogen,con/M-Progest Acet | 26 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 14 |
| Risedronate Sodium | Risedronate Sodium | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 12 |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Glipizide | Glipizide | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Nabumetone | Nabumetone | 17 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Protriptyline Hcl | Protriptyline Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $560.13 · 25 records | Novartis Pharmaceuticals Corporation | CREON, ELIQUIS, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, Kerendia, Korlym, LEQVIO, LINZESS, NURTEC ODT, QULIPTA, Symbravo, TEPEZZA, THINPREP 2000 PROCESSOR, TZIELD, UBRELVY, VRAYLAR, VYEPTI, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error